Reduction in actinic keratoses following 9-valent human papilloma virus vaccination.

Dermatol Ther

Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.

Published: July 2020

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13454DOI Listing

Publication Analysis

Top Keywords

reduction actinic
4
actinic keratoses
4
keratoses 9-valent
4
9-valent human
4
human papilloma
4
papilloma virus
4
virus vaccination
4
reduction
1
keratoses
1
9-valent
1

Similar Publications

Actinic keratosis (AK) is a precursor to invasive squamous cell carcinoma, making early diagnosis and treatment essential to prevent progression. Among available therapeutic options, nicotinamide (NAM) has shown potential in reducing AK progression. NAM is a precursor of nicotinamide adenine dinucleotide (NAD), which activates sirtuin (SIRT)1, a protein with anti-cancer properties.

View Article and Find Full Text PDF

Background: Conventional photodynamic therapy (cPDT) is an effective treatment option for field cancerization and multiple actinic keratoses (AK). The main side effect of cPDT is pain during illumination which in severe cases might necessitate early termination of treatment. Modification of treatment parameters such as light dose and fluence rate is a promising approach to mitigate PDT-associated pain.

View Article and Find Full Text PDF

Background: The Yunnan-Guizhou Plateau's high-altitude setting is characterized by intense solar ultraviolet radiation, a significant environmental stressor that frequently leads to skin barrier damage. This damage presents clinically as erythema, itching, and desquamation, underscoring the need for effective reparative interventions.

Aims: The objective of this study was to assess the therapeutic efficacy of a novel treatment protocol that integrates non-crosslinked hyaluronic acid (HA) injection with microneedle application of human epidermal growth factor (hEGF) for the restoration of skin barrier function in regions of high altitude.

View Article and Find Full Text PDF
Article Synopsis
  • Recent FDA approval of difluoromethylornithine (DFMO) has sparked interest in its potential for preventing various cancers, including keratinocyte carcinomas (KCs), beyond its initial purpose for neuroblastoma in children.
  • A systematic review of 12 studies involving 1,618 predominantly Caucasian patients revealed mixed results, with oral DFMO showing a significant reduction in KCs in only 24% of cases, while topical DFMO showed modest effectiveness in reducing actinic keratosis.
  • Overall, the current evidence does not strongly support the use of oral DFMO, whereas topical DFMO may offer a better option for certain patients in preventing skin cancer.
View Article and Find Full Text PDF
Article Synopsis
  • Facial pigmented skin lesions are common, especially in South-European countries, and can be either malignant or benign; diagnosing them can be challenging, even for specialists like dermatologists.* -
  • A study was conducted to assess the impact of a one-day dermoscopy training course on ophthalmologists, focusing on their ability to evaluate periorbital pigmented lesions through clinical and dermoscopic analysis.* -
  • Results showed that before the training, ophthalmologists had an accuracy of 63.7%, but after the course, their sensitivity improved, indicating a positive effect of the training on their diagnostic skills.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!